drugset / Trial / NCT05523128
The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
NaSingle-groupOpen-labelTreatment
Summary
A non-randomized, open-label, dose-escalation study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS802 in hemophilia A subjects with endogenous FVIII ≤2%.
Timeline
- Start
- 2022-09-29
- Primary completion
- 2025-10
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZS802 | Gene therapy (AAV / viral vector) | 2e+13 vg/kg | Intravenous |
| Subject | ZS802 | Gene therapy (AAV / viral vector) | 6e+13 vg/kg | Intravenous |